Biomarkers /
HDAC9
Overview
HDAC9 is altered in 0.50% of all cancers with breast invasive ductal carcinoma, cutaneous melanoma, mixed lobular and ductal breast carcinoma, conventional glioblastoma multiforme, and breast invasive lobular carcinoma having the greatest prevalence of alterations [3].
The most common alterations in HDAC9 are HDAC9 Mutation (1.83%), HDAC9 Amplification (2.19%), HDAC9 R679Q (0.10%), HDAC9 A856D (0.18%), and HDAC9 D957N (0.13%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.